Evoke Pharma, Inc. (EVOK) Earnings History
Annual and quarterly earnings data from 2011 to 2024
Loading earnings history...
EVOK EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
EVOK Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 96.5% | -50.8% | -52.2% |
| 2023 | 96.1% | -143.4% | -150.4% |
| 2022 | 85.2% | -310.4% | -327.8% |
| 2021 | 79.7% | -503.8% | -527.7% |
| 2020 | -276.7% | -56678.3% | -57144.5% |
Download Data
Export EVOK earnings history in CSV or JSON format
Free sign-in required to download data
Evoke Pharma, Inc. (EVOK) Earnings Overview
As of May 8, 2026, Evoke Pharma, Inc. (EVOK) reported trailing twelve-month net income of -$5M, reflecting +90.0% year-over-year growth. The company earned $-2.04 per diluted share over the past four quarters, with a net profit margin of -52.2%.
Looking at the long-term picture, EVOK's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2012.
Evoke Pharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRPO (-$1M net income, -26.9% margin), AYTU (-$24M net income, -20.4% margin), TLSA (-$34M net income), EVOK has room to improve margins relative to the peer group. Compare EVOK vs PRPO →
EVOK Earnings vs Peers
Earnings metrics vs comparable public companies
EVOK Historical Earnings Data (2011–2024)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$5M | +31.3% | -$5M | $-2.81 | -52.2% | -50.8% |
| 2023 | -$8M | +5.3% | -$7M | $-27.97 | -150.4% | -143.4% |
| 2022 | -$8M | +3.7% | -$8M | $-31.16 | -327.8% | -310.4% |
| 2021 | -$9M | +35.1% | -$8M | $-40.40 | -527.7% | -503.8% |
| 2020 | -$13M | -84.6% | -$13M | $-74.91 | -57144.5% | -56678.3% |
| 2019 | -$7M | +5.8% | -$7M | $-45.84 | - | - |
| 2018 | -$8M | +38.1% | -$8M | $-65.62 | - | - |
| 2017 | -$12M | -13.8% | -$11M | $-118.21 | - | - |
| 2016 | -$11M | +11.3% | -$11M | $-165.75 | - | - |
| 2015 | -$12M | +8.5% | -$12M | $-269.13 | - | - |
See EVOK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVOK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EVOK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEVOK — Frequently Asked Questions
Quick answers to the most common questions about buying EVOK stock.
Is EVOK growing earnings?
EVOK EPS is $-2.04, with earnings growth accelerating to +90.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-5M.
What are EVOK's profit margins?
Evoke Pharma, Inc. net margin is -52.2%, with operating margin at -50.8%. Below-average margins reflect competitive or cost pressures.
How consistent are EVOK's earnings?
EVOK earnings data spans 2011-2024. The accelerating earnings trend is +90.0% YoY. Historical data enables comparison across business cycles.